Skip To Main Content
Barbara Lupo on Muck Rack

Barbara Lupo

As seen in: Nature, Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer - Nature

|
By Andrea Bertotti, Eniko Papp, Sian Jones Verified, Vilmos Adleff, Valsamo Anagnostou, Barbara Lupo, Mark Sausen, Jillian Phallen, Carolyn Hruban, Collin Tokheim, Noushin Niknafs, Monica C Nesselbush, Francesco Sassi, Francesca Cottino, Giorgia Migliardi, Eugenia R. Zanella, Dario Ribero, Nadia Russolillo, Alfredo Mellano, Andrea Muratore Verified, Gianluca Paraluppi, Mauro Salizzoni, Silvia Marsoni, Qing Li, Rachel Karchin, Robert B. Scharpf, Andrea Sartore-Bianchi, Salvatore Siena, Livio Trusolino, Victor E. Velculescu, Karli Lytle, Michael Kragh, Johan Lantto, Andrea Cassingena
| Nature Verified
Correction to: Nature https://doi.org/10.1038/nature14969 Published online 30 September 2015 In Extended Data Fig. 8 of this article, a micrograph shown in the left column (panel AZD) was inadvertently duplicated during figure preparation. The intended image was meant to show phospho-ERK (P-ERK) levels in a MAP2K1-mutant patient-derived xenograft (PDX) exposed to the MEK inhibitor AZD6244 (AZD). However, this image was accidentally overlaid with a micrograph from Extended Data Fig.
Open in Who Shared Issue with article?

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype

|
By Barbara Lupo, of Torino, Francesco Sassi, Marika Pinnelli
| Science Magazine Verified
Tumor cells hunker down to escape Targeted therapy inhibiting pathways involved in tumor growth is becoming increasingly common. This includes inhibitors of the epidermal growth factor receptor, which are used for a variety of tumor types including colorectal cancer. Unfortunately, the treatment’s effects are often incomplete such that residual cancer cells stay behind and contribute to relapse. Lupo et al.
Open in Who Shared Issue with article?
See all 2 articles